|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Deltagen (DGEN) Reports 2012 Second Quarter Financial Results
9/19/2012 9:16:36 AM
SAN MATEO, Calif.--(BUSINESS WIRE)--Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended June 30, 2012. Revenues: The Company’s consolidated revenues for the three months ended June 30, 2012 totaled $0.220 million. The revenues in the second quarter of 2012 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company’s DeltaOneTM program. The consolidated revenues for the period included $0.018 million for Benten BioServices, Inc. ("Benten BioServices") and $0.008 million for Xenopharm, Inc. (“Xenopharm”), both of which were wholly-owned subsidiaries of the Company as of June 30, 2012. The revenues for the second quarter of 2012 reflect delays in international shipments of knockout mice that had been scheduled for delivery and invoicing in the second quarter, which delays had been caused by unusually high temperatures that risked the health and viability of the knockout mice. The revenues associated with such delayed shipments, which total approximately $0.100 million, are expected to be recognized in the third quarter of 2012.
|
|
|
|
|
|
|
|
|
|
|